Introduction
Cholera remains a major global health challenge, particularly in regions with inadequate sanitation. While vaccines are available, current options for the O139 serogroup often face issues with cross-protection and "residual virulence"—where live-attenuated strains still cause mild symptoms. This study details the development of NFYY101, a safer, genetically engineered vaccine candidate designed to provide robust immunity without the side effects of traditional attenuated strains.
Genetic Engineering Strategy
The researchers employed a precise two-step strategy using homologous recombination and suicide plasmids to modify the virulent wild-type strain O139-ZJ9693.
First, they performed a "clean sweep" by deleting a massive 39kb chromosomal segment. This region contained the toxin-linked cryptic (TLC) element, the cholera toxin (CTX) genetic element, and the repeats in toxin (RTX) cluster—all major drivers of pathogenicity.
Second, they strategically re-inserted two essential genes: ctxB, which encodes the non-toxic but highly immunogenic B subunit of the cholera toxin, and rstR, which provides immunity against re-infection by wild-type phages. This ensures the vaccine strain remains stable and cannot revert to a virulent state in the environment.
Safety and Expression Results
The resulting strain, NFYY101, was rigorously tested for both its ability to produce protective antigens and its safety profile.
Antigen Expression
Using GM1-ELISA, the team confirmed that NFYY101 expresses the CTB protein at levels comparable to the original virulent strain. This is critical for ensuring the vaccine can effectively "train" the immune system to recognize V. cholerae.
In Vitro and In Vivo Safety
Safety was evaluated using both cellular and animal models. In Hep-2 human epithelial cell cultures, NFYY101 showed no cytotoxic effects, unlike the parent strain which caused characteristic "cell rounding."
The most definitive proof of attenuation came from the rabbit ileal loop model. While the virulent parent strain caused significant fluid accumulation and intestinal congestion, the engineered NFYY101 strain produced no reaction, behaving identically to the negative control.
Conclusion
The successful construction of NFYY101 represents a significant step toward a safer O139 cholera vaccine. By simultaneously removing multiple virulence factors and "locking" the strain against phage re-infection, the researchers have created a candidate that balances high immunogenicity with an exceptional safety profile. Future work will focus on long-term genetic stability and evaluating the protective immune response in challenge models.
Summary updated